Elanco Animal Health (ELAN) Stock Forecast, Price Target & Predictions
ELAN Stock Forecast
Elanco Animal Health stock forecast is as follows: an average price target of $25.83 (represents a 78.51% upside from ELAN’s last price of $14.47) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
ELAN Price Target
The average price target for Elanco Animal Health (ELAN) is $25.83 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $37.00 to $16.00. This represents a potential 78.51% upside from ELAN's last price of $14.47.
ELAN Analyst Ratings
According to 5 Wall Street analysts, Elanco Animal Health's rating consensus is 'Buy'. The analyst rating breakdown for ELAN stock is 0 'Strong Buy' (0.00%), 3 'Buy' (60.00%), 1 'Hold' (20.00%), 1 'Sell' (20.00%), and 0 'Strong Sell' (0.00%).
Elanco Animal Health Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 01, 2024 | David Westenberg | Piper Sandler | $16.00 | $14.43 | 10.88% | 10.57% |
| May 13, 2024 | David Westenberg | Piper Sandler | $19.00 | $17.00 | 11.76% | 31.31% |
| Mar 12, 2024 | David Westenberg | Piper Sandler | $18.00 | $15.77 | 14.14% | 24.40% |
| Jan 05, 2024 | Jonathan Block | Stifel Nicolaus | $20.00 | $15.45 | 29.45% | 38.22% |
| Sep 12, 2022 | - | Barclays | $18.00 | $15.00 | 20.00% | 24.40% |
| Aug 16, 2022 | David Westenberg | Piper Sandler | $21.00 | $19.08 | 10.06% | 45.13% |
| Jul 18, 2022 | - | J.P. Morgan | $32.00 | $20.14 | 58.89% | 121.15% |
| Jun 24, 2022 | - | Stifel Nicolaus | $22.00 | $19.94 | 10.33% | 52.04% |
| May 19, 2022 | - | Goldman Sachs | $32.00 | $23.35 | 37.04% | 121.15% |
| May 17, 2022 | - | Morgan Stanley | $37.00 | $23.73 | 55.92% | 155.70% |
The latest Elanco Animal Health stock forecast, released on Jul 01, 2024 by David Westenberg from Piper Sandler, set a price target of $16.00, which represents a 10.88% increase from the stock price at the time of the forecast ($14.43), and a 10.57% increase from ELAN last price ($14.47).
Elanco Animal Health Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 4 |
| Avg Price Target | - | $16.00 | $18.25 |
| Last Closing Price | $14.47 | $14.47 | $14.47 |
| Upside/Downside | -100.00% | 10.57% | 26.12% |
In the current month, the average price target of Elanco Animal Health stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Elanco Animal Health's last price of $14.47. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 01, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| May 13, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| May 09, 2024 | Bank of America Securities | Buy | Buy | Hold |
| May 09, 2024 | Barclays | Overweight | Overweight | Hold |
| Jan 17, 2024 | Goldman Sachs | Sell | Sell | Hold |
| Apr 20, 2023 | Barclays | Equal-Weight | Overweight | Upgrade |
| Sep 12, 2022 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Aug 18, 2022 | Morgan Stanley | Overweight | Overweight | Downgrade |
| Aug 16, 2022 | Piper Sandler | Neutral | Neutral | Hold |
| May 19, 2022 | Goldman Sachs | Buy | Buy | Hold |
Elanco Animal Health's last stock rating was published by Piper Sandler on Jul 01, 2024. The company gave ELAN a "Neutral" rating, the same as its previous rate.
Elanco Animal Health Financial Forecast
Elanco Animal Health Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.07B | $1.06B | $1.26B | $988.00M | $1.03B | - | $1.23B | $1.11B | $1.13B | $1.28B | $1.24B | $1.14B | $889.60M | $586.30M | $657.70M | $787.00M | $771.30M |
| Avg Forecast | $1.12B | $1.14B | $1.25B | $1.28B | $1.07B | $1.09B | $1.18B | $1.22B | $1.01B | $1.04B | $1.15B | $1.19B | $1.00B | $1.04B | $1.04B | $1.19B | $980.94M | $1.03B | $1.18B | $1.22B | $1.10B | $1.08B | $1.24B | $1.16B | $1.05B | $913.80M | $575.44M | $721.62M | $790.45M | $764.69M |
| High Forecast | $1.13B | $1.15B | $1.27B | $1.29B | $1.08B | $1.10B | $1.19B | $1.23B | $1.02B | $1.05B | $1.16B | $1.20B | $1.01B | $1.05B | $1.05B | $1.21B | $990.50M | $1.04B | $1.18B | $1.24B | $1.13B | $1.10B | $1.27B | $1.18B | $1.08B | $931.65M | $586.68M | $735.72M | $805.90M | $779.63M |
| Low Forecast | $1.12B | $1.14B | $1.25B | $1.27B | $1.06B | $1.09B | $1.17B | $1.21B | $1.00B | $1.03B | $1.14B | $1.18B | $988.87M | $1.03B | $1.03B | $1.19B | $976.28M | $1.03B | $1.18B | $1.19B | $1.07B | $1.05B | $1.21B | $1.13B | $1.03B | $889.15M | $559.92M | $702.15M | $769.13M | $744.06M |
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 3 | 6 | 4 | 6 | 7 | 7 | 8 | 7 | 10 | 9 | 6 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 1.02% | 1.05% | 1.01% | 1.00% | - | 1.01% | 1.01% | 1.05% | 1.03% | 1.07% | 1.08% | 0.97% | 1.02% | 0.91% | 1.00% | 1.01% |
Elanco Animal Health's average Quarter revenue forecast for Dec 23 based on 7 analysts is $1.00B, with a low forecast of $988.87M, and a high forecast of $1.01B. ELAN's average Quarter revenue forecast represents a -6.21% decrease compared to the company's last Quarter revenue of $1.07B (Sep 23).
Elanco Animal Health EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 3 | 6 | 4 | 6 | 7 | 7 | 8 | 7 | 10 | 9 | 6 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $42.00M | $166.00M | $346.00M | $136.00M | $211.00M | - | $345.00M | $108.00M | $100.00M | $-6.00M | $183.00M | $-35.50M | $-28.60M | $28.60M | $30.20M | $97.80M | $84.90M |
| Avg Forecast | $204.31M | $208.41M | $228.46M | $233.47M | $194.38M | $198.79M | $214.65M | $221.70M | $183.94M | $188.69M | $209.23M | $351.45M | $182.55M | $189.47M | $189.12M | $319.50M | $178.78M | $89.38M | $214.61M | $290.46M | $82.59M | $81.25M | $-5.54M | $78.77M | $-23.67M | $-26.22M | $15.73M | $39.64M | $97.80M | $71.84M |
| High Forecast | $206.30M | $210.44M | $230.68M | $235.74M | $196.27M | $200.73M | $216.74M | $223.85M | $185.73M | $190.52M | $211.26M | $421.74M | $184.43M | $191.31M | $190.96M | $383.40M | $180.52M | $107.25M | $214.61M | $348.55M | $99.11M | $97.50M | $-4.43M | $94.52M | $-18.93M | $-20.97M | $18.88M | $47.56M | $117.36M | $86.21M |
| Low Forecast | $203.34M | $207.42M | $227.37M | $232.36M | $193.46M | $197.85M | $213.63M | $220.64M | $183.06M | $187.80M | $208.23M | $281.16M | $180.23M | $188.57M | $188.22M | $255.60M | $177.93M | $71.50M | $214.61M | $232.37M | $66.07M | $65.00M | $-6.65M | $63.02M | $-28.40M | $-31.46M | $12.58M | $31.71M | $78.24M | $57.47M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.22% | 0.88% | 1.08% | 0.76% | 2.36% | - | 1.19% | 1.31% | 1.23% | 1.08% | 2.32% | 1.50% | 1.09% | 1.82% | 0.76% | 1.00% | 1.18% |
7 analysts predict ELAN's average Quarter EBITDA for Dec 23 to be $182.55M, with a high of $184.43M and a low of $180.23M. This is 334.65% upper than Elanco Animal Health's previous annual EBITDA (Sep 23) of $42.00M.
Elanco Animal Health Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 3 | 6 | 4 | 6 | 7 | 7 | 8 | 7 | 10 | 9 | 6 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-1.10B | $-97.00M | $103.00M | $-54.00M | $-49.00M | - | $48.00M | $-97.00M | $-104.00M | $-210.00M | $-61.00M | $-322.80M | $-135.00M | $-53.20M | $-49.10M | $-9.50M | $10.00M |
| Avg Forecast | $118.61M | $133.43M | $143.32M | $182.85M | $95.11M | $93.76M | $147.56M | $163.86M | $79.31M | $60.49M | $118.45M | $56.42M | $51.66M | $61.59M | $23.26M | $51.29M | $62.95M | $-92.95M | $125.11M | $46.63M | $-74.18M | $-84.50M | $-193.85M | $-26.26M | $-215.20M | $-123.75M | $-29.26M | $-64.44M | $-9.50M | $8.46M |
| High Forecast | $120.11M | $135.12M | $145.13M | $185.17M | $96.32M | $94.95M | $149.43M | $165.93M | $80.32M | $65.99M | $119.95M | $67.70M | $67.16M | $62.37M | $23.56M | $61.55M | $63.75M | $-74.36M | $125.11M | $55.95M | $-59.34M | $-67.60M | $-155.08M | $-21.01M | $-172.16M | $-99.00M | $-23.41M | $-51.55M | $-7.60M | $10.15M |
| Low Forecast | $117.88M | $132.61M | $142.43M | $181.72M | $94.53M | $93.18M | $146.65M | $162.84M | $78.82M | $54.98M | $117.72M | $45.14M | $41.33M | $61.21M | $23.12M | $41.03M | $62.56M | $-111.54M | $125.11M | $37.30M | $-89.01M | $-101.40M | $-232.62M | $-31.51M | $-258.24M | $-148.50M | $-35.11M | $-77.33M | $-11.40M | $6.77M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -17.79% | -4.17% | 2.01% | -0.86% | 0.53% | - | 1.03% | 1.31% | 1.23% | 1.08% | 2.32% | 1.50% | 1.09% | 1.82% | 0.76% | 1.00% | 1.18% |
Elanco Animal Health's average Quarter net income forecast for Jun 23 is $23.26M, with a range of $23.12M to $23.56M. ELAN's average Quarter net income forecast represents a -77.42% decrease compared to the company's last Quarter net income of $103.00M (Mar 23).
Elanco Animal Health SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 3 | 6 | 4 | 6 | 7 | 7 | 8 | 7 | 10 | 9 | 6 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $313.00M | $353.00M | $327.00M | $303.00M | $298.00M | - | $320.00M | $329.00M | $342.00M | $385.00M | $348.00M | $374.10M | $277.70M | $162.80M | $364.00M | $237.30M | $243.00M |
| Avg Forecast | $319.29M | $325.70M | $357.03M | $364.86M | $303.78M | $310.67M | $335.45M | $346.46M | $287.45M | $294.89M | $326.97M | $376.14M | $285.29M | $296.10M | $295.55M | $341.94M | $279.40M | $305.66M | $335.38M | $310.86M | $251.59M | $277.88M | $355.38M | $149.79M | $249.40M | $254.56M | $89.54M | $477.75M | $237.30M | $205.62M |
| High Forecast | $322.40M | $328.87M | $360.51M | $368.42M | $306.74M | $313.69M | $338.72M | $349.84M | $290.25M | $297.75M | $330.16M | $451.36M | $288.22M | $298.98M | $298.43M | $410.33M | $282.12M | $366.80M | $335.38M | $373.03M | $301.91M | $333.45M | $426.46M | $179.75M | $299.28M | $305.47M | $107.45M | $573.30M | $284.76M | $246.74M |
| Low Forecast | $317.77M | $324.15M | $355.33M | $363.13M | $302.33M | $309.19M | $333.86M | $344.81M | $286.09M | $293.48M | $325.42M | $300.91M | $281.66M | $294.69M | $294.14M | $273.55M | $278.07M | $244.53M | $335.38M | $248.69M | $201.27M | $222.30M | $284.31M | $119.83M | $199.52M | $203.65M | $71.63M | $382.20M | $189.84M | $164.49M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.06% | 1.19% | 0.96% | 1.08% | 0.97% | - | 1.03% | 1.31% | 1.23% | 1.08% | 2.32% | 1.50% | 1.09% | 1.82% | 0.76% | 1.00% | 1.18% |
Elanco Animal Health's average Quarter SG&A projection for Dec 23 is $285.29M, based on 7 Wall Street analysts, with a range of $281.66M to $288.22M. The forecast indicates a -8.85% fall compared to ELAN last annual SG&A of $313.00M (Sep 23).
Elanco Animal Health EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 3 | 6 | 4 | 6 | 7 | 7 | 8 | 7 | 10 | 9 | 6 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-2.22 | $-0.20 | $0.21 | $-0.11 | $-0.10 | - | $0.10 | $-0.20 | $-0.21 | $-0.43 | $-0.12 | $-0.66 | $-0.29 | $-0.13 | $-0.12 | $-0.03 | $0.03 |
| Avg Forecast | $0.24 | $0.27 | $0.29 | $0.37 | $0.19 | $0.19 | $0.30 | $0.33 | $0.16 | $0.12 | $0.24 | $0.27 | $0.10 | $0.12 | $0.05 | $0.29 | $0.13 | $0.16 | $0.25 | $0.35 | $0.17 | $0.17 | $0.27 | $0.23 | $0.10 | $0.12 | $0.04 | $0.24 | $0.23 | $0.26 |
| High Forecast | $0.24 | $0.27 | $0.29 | $0.37 | $0.19 | $0.19 | $0.30 | $0.34 | $0.16 | $0.13 | $0.24 | $0.28 | $0.14 | $0.13 | $0.05 | $0.29 | $0.13 | $0.16 | $0.25 | $0.36 | $0.17 | $0.17 | $0.28 | $0.23 | $0.10 | $0.12 | $0.04 | $0.24 | $0.23 | $0.26 |
| Low Forecast | $0.24 | $0.27 | $0.29 | $0.37 | $0.19 | $0.19 | $0.30 | $0.33 | $0.16 | $0.11 | $0.24 | $0.27 | $0.08 | $0.12 | $0.05 | $0.28 | $0.13 | $0.16 | $0.25 | $0.34 | $0.16 | $0.16 | $0.26 | $0.22 | $0.10 | $0.12 | $0.04 | $0.23 | $0.22 | $0.25 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -17.81% | -4.25% | 0.74% | -0.86% | -0.63% | - | 0.28% | -1.19% | -1.27% | -1.60% | -0.53% | -6.68% | -2.40% | -3.48% | -0.51% | -0.13% | 0.12% |
According to 6 Wall Street analysts, Elanco Animal Health's projected average Quarter EPS for Jun 23 is $0.05, with a low estimate of $0.05 and a high estimate of $0.05. This represents a -77.59% decrease compared to ELAN previous annual EPS of $0.21 (Mar 23).
Elanco Animal Health Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ESPR | Esperion Therapeutics | $1.91 | $16.00 | 737.70% | Buy |
| PCRX | Pacira BioSciences | $13.11 | $43.00 | 227.99% | Hold |
| IRWD | Ironwood Pharmaceuticals | $4.57 | $11.67 | 155.36% | Buy |
| ELAN | Elanco Animal Health | $14.47 | $25.83 | 78.51% | Buy |
| LNTH | Lantheus | $105.55 | $146.25 | 38.56% | Buy |
| ALKS | Alkermes | $27.66 | $35.50 | 28.34% | Buy |
| ITCI | Intra-Cellular Therapies | $75.38 | $94.00 | 24.70% | Buy |
| CTLT | Catalent | $59.62 | $74.30 | 24.62% | Hold |
| VTRS | Viatris | $11.66 | $13.75 | 17.92% | Hold |
| COLL | Collegium Pharmaceutical | $37.50 | $41.50 | 10.67% | Buy |
| PBH | Prestige Consumer Healthcare | $74.12 | $82.00 | 10.63% | Buy |
| TEVA | Teva Pharmaceutical Industries | $18.41 | $19.17 | 4.13% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| HLN | Haleon | $10.51 | $9.15 | -12.94% | Buy |
| PAHC | Phibro Animal Health | $21.99 | $18.67 | -15.10% | Buy |
ELAN Forecast FAQ
Is Elanco Animal Health a good buy?
Yes, according to 5 Wall Street analysts, Elanco Animal Health (ELAN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 60.00% of ELAN's total ratings.
What is ELAN's price target?
Elanco Animal Health (ELAN) average price target is $25.83 with a range of $16 to $37, implying a 78.51% from its last price of $14.47. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Elanco Animal Health stock go up soon?
According to Wall Street analysts' prediction for ELAN stock, the company can go up by 78.51% (from the last price of $14.47 to the average price target of $25.83), up by 155.70% based on the highest stock price target, and up by 10.57% based on the lowest stock price target.
Can Elanco Animal Health stock reach $20?
ELAN's average twelve months analyst stock price target of $25.83 supports the claim that Elanco Animal Health can reach $20 in the near future.
What are Elanco Animal Health's analysts' financial forecasts?
Elanco Animal Health's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $4.55B (high $4.6B, low $4.53B), average EBITDA is $829.52M (high $837.6M, low $825.58M), average net income is $500.29M (high $506.63M, low $497.2M), average SG&A $1.3B (high $1.31B, low $1.29B), and average EPS is $1.01 (high $1.03, low $1.01). ELAN's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $4.8B (high $4.85B, low $4.78B), average EBITDA is $874.64M (high $883.16M, low $870.49M), average net income is $578.21M (high $585.53M, low $574.64M), average SG&A $1.37B (high $1.38B, low $1.36B), and average EPS is $1.17 (high $1.18, low $1.16).
Did the ELAN's actual financial results beat the analysts' financial forecasts?
Based on Elanco Animal Health's last annual report (Dec 2023), the company's revenue was $4.42B, beating the average analysts forecast of $4.27B by 3.39%. Apple's EBITDA was $326M, missing the average prediction of $880.64M by -62.98%. The company's net income was $-1.231B, missing the average estimation of $187.81M by -755.46%. Apple's SG&A was $1.28B, beating the average forecast of $1.22B by 5.42%. Lastly, the company's EPS was $-2.5, missing the average prediction of $0.561 by -545.42%. In terms of the last quarterly report (Sep 2023), Elanco Animal Health's revenue was $1.07B, beating the average analysts' forecast of $1.04B by 2.73%. The company's EBITDA was $42M, missing the average prediction of $189.47M by -77.83%. Elanco Animal Health's net income was $-1.096B, missing the average estimation of $61.59M by -1879.45%. The company's SG&A was $313M, beating the average forecast of $296.1M by 5.71%. Lastly, the company's EPS was $-2.22, missing the average prediction of $0.125 by -1881.27%